Merck & Co., Inc., Cardiome Pharma Corp. Heart Drug Gets Positive EU Review

June 25, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, June 25 (Reuters) - The European Medicines Agency has recommended Merck & Co's (MRK.N) drug Brinavess, or vernakalant, as a treatment for acute atrial fibrillation, or irregular heart beats, the London-based regulator said on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Merck & Co.